Comerica Bank
RXRX icon

Comerica Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

Comerica Bank’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.8K Sell
2,641
-883
-25% -$4.37K ﹤0.01% 3223
2025
Q3 		$17.2K Sell
3,524
-600
-15% -$3.15K ﹤0.01% 3125
2025
Q2 		$20.9K Buy
4,124
+1,497
+57% +$7.35K ﹤0.01% 3041
2025
Q1 		$13.9K Sell
2,627
-118
-4% -$860 ﹤0.01% 3108
2024
Q4 		$18.6K Buy
2,745
+268
+11% +$1.8K ﹤0.01% 3055
2024
Q3 		$16.3K Sell
2,477
-1,174
-32% -$8.42K ﹤0.01% 3080
2024
Q2 		$27.4K Buy
3,651
+65
+2% +$567 ﹤0.01% 2914
2024
Q1 		$35.8K Buy
3,586
+748
+26% +$8.33K ﹤0.01% 2857
2023
Q4 		$28K Buy
2,838
+2,572
+967% +$18.3K ﹤0.01% 2884
2023
Q3 		$2.04K Buy
+266
New +$2.65K ﹤0.01% 3567

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Comerica Bank's RXRX Position: Q4 2025 in Review

Comerica Bank reduced its Recursion Pharmaceuticals (RXRX) stake by 25% in Q4 2025, selling an estimated $4.37K and leaving 2,641 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3223.

Comerica Bank first reported a position in RXRX in Q3 2023 and has held it in 10 quarters since. The position peaked at $35.8K in Q1 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Comerica Bank held 2,641 shares of Recursion Pharmaceuticals worth $10.8K as of Q4 2025.
  • Comerica Bank sold 883 Recursion Pharmaceuticals shares in Q4 2025, an estimated $4.37K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3223 holding.
  • Comerica Bank first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Comerica Bank's Recursion Pharmaceuticals position peaked at $35.8K in Q1 2024.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.